The management of hormone-relapsed prostate cancer.
Clarke
N W
NW
Christie Hospital NHS Trust and Salford Royal Hospitals NHS Trust, Manchester, UK. Mandy.Kenyon@christie-tr.nwest.nhs.uk
D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000209:etiology; D001859:Bone Neoplasms / Q000556:secondary; D019008:Drug Resistance, Neoplasm; D005598:Fractures, Spontaneous / Q000209:etiology; D006801:Humans; D007415:Intestinal Obstruction / Q000209:etiology / Q000628:therapy; D008209:Lymphedema / Q000209:etiology / Q000628:therapy; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010146:Pain / Q000209:etiology / Q000517:prevention & control; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000150:complications / Q000188:drug therapy*; D012002:Rectal Diseases / Q000209:etiology / Q000628:therapy; D013117:Spinal Cord Compression / Q000209:etiology / Q000628:therapy; D014517:Ureteral Obstruction / Q000209:etiology
D018931:Antineoplastic Agents, Hormonal